Open Orphan #ORPH – hVIVO to present at 2020 ERS International Congress
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce that its subsidiary, hVIVO, will be presenting at the European Respiratory Society Congress being held on 7th – 9th September, 2020. The presentation will […]
Cathal Friel, Open Orphan #ORPH CEO confirms to Proactive Investors that the hVIVO deal is done
Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. Cathal also provides some news on the Genomic Database and explains how he expects hVIVO to make a profit.
Open Orphan plc (ORPH) Investor Event Attendance and Presentation
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at The London Investor Show at Novotel London West, London, W6 8DR this Friday 25th October 2019. Maurice Treacy, Open Orphan’s Chief Commercial Officer, will be in attendance and will be presenting in Conference […]
Open Orphan #ORPH signs strategic collaboration agreement with Empiric Logic
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed a new strategic collaboration agreement (“the Collaboration”) with Empiric Logic to build on the earlier work performed by Open Orphan and complete the build out of Open Orphan’s Health Data platform, Europe’s first rare disease, advocacy-led genomic database. Empiric […]